Diaverum welcomes M42 as its new shareholder
Diaverum is announcing today that M42 has entered into a definitive agreement to acquire 100% of the company from Bridgepoint.Diaverum, acquired by Bridgepoint in 2007, is a leading global renal care company that provides essential, life-sustaining dialysis treatments to patients in around 440 clinics across 23 countries worldwide. The company’s main focus is haemodialysis, in conjunction with a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to the coordination of patients’ comorbidities and their preparation for kidney transplantation. Diaverum